Remarkably, the clinically validated PP2A inhibitors LB100 and LB102, in combination with TKIs, act synergistically to inhibit the growth of CML LSCs [241] and BCR-ABL+ ALL patient cells [242]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.